Author: Stoots, Sarah Abramson; Lief, Lindsay; Erkan, Doruk
Title: Clinical Insights into Diffuse Alveolar Hemorrhage in Antiphospholipid Syndrome Cord-id: cg2i2bae Document date: 2019_9_6
ID: cg2i2bae
Snippet: PURPOSE OF REVIEW: Diffuse alveolar hemorrhage (DAH) is a rare but devastating manifestation of antiphospholipid syndrome (APS) patients with or without other systemic autoimmune diseases. Data regarding diagnosis and treatment are limited to case series. We review diagnostic and therapeutic strategies employed in APS patients with DAH and discuss our experience in managing these complex patients. RECENT FINDINGS: Pulmonary capillaritis likely contributes to the pathogenesis, however is only obs
Document: PURPOSE OF REVIEW: Diffuse alveolar hemorrhage (DAH) is a rare but devastating manifestation of antiphospholipid syndrome (APS) patients with or without other systemic autoimmune diseases. Data regarding diagnosis and treatment are limited to case series. We review diagnostic and therapeutic strategies employed in APS patients with DAH and discuss our experience in managing these complex patients. RECENT FINDINGS: Pulmonary capillaritis likely contributes to the pathogenesis, however is only observed in half of the biopsies. Corticosteroids induce remission in the majority of patients, however almost half recur and require a steroid-sparing immunosuppressive to maintain remission. Cyclophosphamide- or rituximab-based regimens achieve the highest remission rates (50%); other strategies include intravenous immunoglobulin, plasmapheresis, mycophenolate mofetil, and/or azathioprine. SUMMARY: Given the rarity of DAH in APS, treatment is guided by interdisciplinary experience. Why certain patients achieve full remission with corticosteroids while others require immunosuppressive agents is unknown; future research should focus on the pathophysiology and optimal management.
Search related documents:
Co phrase search for related documents- acute phase and adenovirus respiratory syncytial virus: 1, 2, 3, 4, 5
- acute phase and adhesion molecule: 1, 2
- acute phase and long term follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- acute phase and long term management: 1, 2, 3, 4, 5, 6
- acute phase and lung biopsy: 1, 2, 3, 4
- acute phase and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- acute phase and lupus anticoagulant: 1
- acute respiratory distress syndrome and additional imaging: 1, 2
- acute respiratory distress syndrome and adenovirus respiratory syncytial virus: 1
- acute respiratory distress syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory distress syndrome and livedoid vasculopathy: 1
- acute respiratory distress syndrome and long term follow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute respiratory distress syndrome and long term management: 1, 2, 3, 4, 5, 6
- acute respiratory distress syndrome and lung biopsy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute respiratory distress syndrome and lung hyperinflation: 1, 2, 3, 4, 5
- acute respiratory distress syndrome and lung microcirculation: 1, 2, 3
- acute respiratory distress syndrome and lupus anticoagulant: 1, 2
- acute respiratory distress syndrome and lupus patient: 1, 2
Co phrase search for related documents, hyperlinks ordered by date